UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

THE DEPENDENCE OF THE CONCENTRATION OF TYPE 2 GLYCOPROTEIN ON THE CONCENTRATION OF ZONULIN IN CROHN'S DISEASE DURING REMISSION OF THE DISEASE

Anna Kagramanova 1, Oleg Knyazev 1,2, Alexandr Novikov 1, Elena Alexandrova 1, Bella Nanaeva 2, Raisa Gudkova 1, Dmitriy Kulakov 1, Asfold Parfenov 1

Affiliations

1 Moscow Clinical Scientific Center named after A.S. Loginov, Moscow, Russian Federation

2 State Scientific Centre of Coloproctology named after A.N. Ryzhyh, Moscow, Russian Federation

Summary

AI Generated

A study of 217 Crohn's disease patients in remission found no correlation between fecal zonulin levels and serum anti-GP2 antibodies (IgA and IgG), markers of intestinal permeability and pancreatic autoimmunity respectively.

Among 217 CD patients in remission (median age 38 years), 35% had elevated fecal zonulin (mean 235.4±11.6 ng/ml), 27.2% had elevated serum IgA anti-GP2 (mean 24.4±1.9 units/ml), and 63% had elevated serum IgG anti-GP2 (mean 19.7±1.1 units/ml).
No correlation was found between fecal zonulin concentration and serum IgA anti-GP2 levels (r=-0.260, p>0.05).
A moderate correlation (r=0.310, p=0.033) was observed between fecal zonulin and serum IgG anti-GP2, though the authors concluded overall there was no correlation between these markers.
Fecal zonulin is used as a noninvasive marker of increased intestinal permeability, while GP2 is the main antigen for pancreatic antibodies associated with Crohn's disease.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Type 2 Glycoprotein (GP2) is a quantitatively predominant membrane protein of excretory granules of pancreatic acinar cells. In a number of studies, it has been demonstrated that this protein is the main antigen for pancreatic antibodies associated with Crohn's disease Zonulin – a protein that can reversibly increase the permeability of the intestinal wall by changing the structure of tight junctions of the lateral surfaces of intestinal epithelial cells. The determination of fecal zonulin is used for noninvasive assessment of increased intestinal permeability. Normal values of fecal zonulin (≤ 110 ng/ml) indicate the absence of damage to the villous surface of the intestinal mucosa and normal density of intercellular contacts

Aims & Methods

The aim of the study was to establish the dependence of the level of type 2 glycoprotein on the level of fecal zonulin (FZ) in the feces of CD patients with exacerbation of the disease.
Material and methods. 217 patients with CD in remission of the disease (Ме age — 38 years) were examined. FZ was evaluated by ELISA (IDK ® Zonulin ELISA Kit, Immunodiagnostik AG, Germany) in ng/ml. Reference values: < 83.15 ng/ml - a variant of the norm, 83.15-110 ng/ml - an elevated level, 110 ng/ml - a high level.
The level of IgG and IgA to GP2 (antibodies to glycoprotein) antigen of pancreatic centroacinar cells (Anti-GP2, IgG, IgA) was determined by ELISA. Reference values: IgG GP-2 less than 10 units/ml, Ig And GP-2 less than 5 units/ml – positive values.

Results

In the stool samples of CD patients during remission in 76 (35%) patients, an increase in the FZ was detected, the average value was 235.4±11.6 ng/ml. In the blood samples of 59 (27.2%) CD patients during remission, an increase in Ig A GP-2 was detected, the average value was 24.4±1.9 units/ml. In the blood samples of 137 CD patients during remission, an increase in Ig G GP-2 was detected, the average value was 19.7±1.1 units/ml. There is no correlation between the concentration of FZ and the concentration of Ig A GP-2 (r-0.260) (p>0.05). There is a moderate correlation force (r-0.310) (p=0.033) between the concentration of FZ and the concentration of Ig G GP-2.

Conclusion

There is no correlation between the concentration of FZ in the feces of CD patients during remission with the concentration of Ig A GP-2 and Ig G GP-2 in the blood serum of patients.

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

Stricturing Crohn's disease

Jimme Klaas Wiggers

Transmural remission improves clinical outcomes up to 5 years in Crohn's disease

Samuel Raimundo Fernandes

Anti-TNF failure in Crohn's disease

Joshua McGuire

THE DEPENDENCE OF THE LEVEL OF GLYCOPROTEIN TYPE 2 ON THE LEVEL OF ZONULIN IN CROHN'S DISEASE

Elena Alexandrova

Fistulising Crohn's disease: Underlying mechanism

Judy Chou

VITAMIN DEFICIENCIES IN CROHN'S DISEASE

Mohamed Borahma

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.